RevBio Awarded a $3.4 Million NIH Grant for Its Novel Regenerative Bone Adhesive to Treat Complex Fractures
LOWELL, Mass.--(BUSINESS WIRE)--Oct 6, 2023--
Stay updated with breaking news from Mcommercialization Readiness Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LOWELL, Mass.--(BUSINESS WIRE)--Oct 6, 2023--
As the Pentagon’s Small Business Strategy makes clear, small companies are key to helping the U.S. ensure its technological superiority.
/PRNewswire/ -- Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, announced today that it has been awarded a $3.4M...
/PRNewswire/ -- Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, announced today that it has been awarded a $3.4M...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 22, 2021-- Vaxess Technologies, Inc., a biotechnology company developing vaccines and therapeutics delivered through a next-generation sustained-release intradermal microneedle patch, announced it was awarded a Commercialization Readiness Program (CRP) grant from the National Institute of Allergy and Infectious Diseases (NIAID grant number SB1AI164584), a part of the U.S. National Institutes of Health (NIH). Vaxess will receive up to $2.85 million over the course of the award if the project milestones are met. The CRP grant will be used to advance the co...